Core Insights - U.S. stocks experienced a decline, with the Dow Jones index dropping over 100 points on Wednesday [1] - Acuity Inc. reported better-than-expected fourth-quarter earnings, with an adjusted EPS of $5.20, surpassing the analyst consensus estimate of $4.84 [1] - Acuity's quarterly net sales grew by 17.1% year-over-year to $1.21 billion, slightly below the analyst consensus estimate of $1.23 billion [1] - Acuity's shares increased by 5.3% to $362.54 following the earnings report [1] Company Performance Highlights - Lithium Americas Corp. shares surged by 17.5% to $6.72 after an agreement with GM and the U.S. Department of Energy regarding its DOE loan [4] - Rezolve AI PLC's shares rose by 15.8% to $5.77 after raising its 2025 revenue target to $150 million ARR and setting a $500 million goal for 2026 [4] - The AES Corporation's shares increased by 14.2% to $15.02 amid reports of BlackRock's Global Infrastructure Partners nearing an acquisition [4] - Sunrun Inc. gained 12.7% to $19.49 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $11 to $21 [4] - Plug Power Inc. shares rose by 12.7% to $2.63 following the delivery of its first 10-megawatt GenEco™ electrolyzer array to Galp [4] - Hycroft Mining Holding Corporation's shares jumped by 10.7% to $6.87 [4] - United States Antimony Corporation shares gained 10.3% to $6.87 [4] - Upexi, Inc. increased by 9.7% to $6.33 [4] - Fluence Energy, Inc. rose by 8.3% to $11.70 [4] - Intellia Therapeutics, Inc. shares increased by 8.1% to $18.67 [4] - Standard Lithium Ltd. shares gained 8.1% to $3.6442 [4] - Zeta Global Holdings Corp. rose by 7.4% to $21.34, announcing plans to acquire Marigold's Enterprise business for up to $325 million [4] - Regeneron Pharmaceuticals, Inc. gained 5.6% to $593.71, with third quarter 2025 financial results set to be reported on Oct. 28 [4]

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).Results were presented at the International ATTR Amyloidosis Annual Meeting for Patients and Doctors. The results were simultaneously published in the New England Journal of Medicine.DataDeep, durable and consistent TTR reductions continue to be observed. Across ...

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors with simultaneous publication in the New England Journal of Medici ...

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measuresCAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-term data from the ongoing Phase 1 tria ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

Group 1 - The article highlights the success of a buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA) made on August 15, which has resulted in a significant increase in the stock's value [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to monitor and buy/sell ratings [1] - The group provides comprehensive financial analyses, including product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1] Group 2 - The author, Edmund Ingham, has over five years of experience in covering biotech, healthcare, and pharma sectors, having prepared detailed reports on more than 1,000 companies [1]

Key Takeaways Intellia completed enrollment in the pivotal phase III HAELO study of lonvo-z for HAE.Top-line HAELO data is expected in early 2026, with a U.S. launch targeted for 1H 2027.First patient in the HAELO study dosed in January 2025, as full enrollment was completed in nine months.Shares of Intellia Therapeutics (NTLA) soared 29.8% yesterday after the company announced that it has completed enrollment in the phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonv ...

Core Points - Intellia Therapeutics, Inc. (NTLA) shares increased by 29.8% to $16.11, with a trading volume higher than average, following a 21.6% gain over the past four weeks [1][2] - The stock's rally was driven by the completion of enrollment in the pivotal phase III HAELO study for its investigational candidate, lonvoguran ziclumeran (lonvo-z), aimed at treating hereditary angioedema (HAE) [2] - Top-line data from the HAELO study is anticipated in the first half of 2026, with a potential biologics license application submission planned for the second half of 2026 [3] - If approved, the company intends to launch lonvo-z in the United States in 2027 [3] - The company is projected to report a quarterly loss of $1.01 per share, reflecting a year-over-year increase of 24.6%, while revenues are expected to reach $14.38 million, up 57.8% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 0.5% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [5] - Intellia Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [6] Industry Context - Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like CG Oncology, Inc. (CGON) [6] - CGON's stock closed 2.9% higher at $38.82, with a 47.8% return over the past month, while its consensus EPS estimate has remained unchanged at -$0.57, representing a 90% decrease compared to the previous year [6][7]

Core Insights - Intellia Therapeutics has completed enrollment in the global Phase 3 HAELO study for lonvoguran ziclumeran (lonvo-z) targeting hereditary angioedema (HAE) with topline data expected in the first half of 2026 [1][2] - The company plans to submit a biologics license application (BLA) in the second half of 2026, aiming for a U.S. launch in the first half of 2027 [1][6] Company Overview - Intellia Therapeutics is a clinical-stage gene editing company focused on CRISPR-based therapies [1][7] - The company aims to address unmet medical needs through innovative gene editing technologies [7] Study Details - The Phase 3 HAELO study is a randomized, double-blind, placebo-controlled trial involving at least 60 adults and adolescents aged 16 years and older with Type I or Type II HAE [2][4] - Key endpoints include the number of HAE attacks and the number of patients achieving attack-free status from week 5 through week 28 [2][4] Treatment Potential - Lonvo-z is designed to be a one-time treatment for HAE, utilizing CRISPR technology to inactivate the KLKB1 gene, which is crucial for preventing HAE attacks [4][5] - Interim Phase 1/2 clinical data indicated significant reductions in attack rates and consistent decreases in kallikrein levels [4] Regulatory Designations - Lonvo-z has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the FDA, Innovation Passport from the U.K. MHRA, and PRIME Designation from the European Medicines Agency [4]

Investment Opportunities - Identifying stocks that can rise 1,000% or more is essential for building significant wealth, as these investments can dramatically increase portfolio value [1][2] - Tronox Holdings Plc (TROX), a major producer of titanium dioxide, is highlighted as a potential investment with a projected return to the $20 range, representing a 4X return from current levels [3] - Intellia Therapeutics Inc. (NTLA) has seen its shares drop significantly but shows potential for a 1,000% upside due to promising drug trials and significant backing from Regeneron Pharmaceuticals Inc. [11][12] - WeRide Inc. (WRD), a leading robotaxi firm in China, is positioned for substantial growth with a potential 1,000% upside through 2030 as it expands into international markets [18] Market Trends - The Chinese auto market is evolving rapidly, with local manufacturers producing advanced vehicles that compete with Western models, particularly in the robotaxi sector [13][14] - The number of self-driving taxis in China is expected to grow significantly, with estimates suggesting up to 4 million robotaxis by 2030 [14] Investment Strategies - A quantitative system called Apogee has been developed to identify high-quality stocks that have fallen significantly but show signs of recovery, focusing on the "down a lot, up a little" strategy [3][21] - The system has already identified several companies with potential for substantial gains, emphasizing the importance of recognizing turnaround signals in stock performance [21]